Who Paid My Doc
Jeffrey Welgoss
Urogynecology and Reconstructive Pelvic Surgery Annandale, VA Medical Doctor
NPI 1194750414 CMS profile 99569
3289 Woodburn Rd, Suite 130, Annandale, VA 22003
General payments
$49,931
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jeffrey Welgoss of Annandale, VA is reported in the CMS Open Payments database as having received $49,931 across 174 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26,398 | 34 | |
| 2024 | General | $11,547 | 28 | |
| 2023 | General | $285 | 3 | |
| 2022 | General | $2,573 | 21 | |
| 2021 | General | $7,758 | 52 | |
| 2020 | General | $896 | 16 | |
| 2019 | General | $474 | 20 |
Beside peers
- Jeffrey Welgoss
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Jeffrey Welgoss were reported at $26,398. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Jeffrey Welgoss | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $474 | $358 | $132–$1,270 | $163 |
| 2020 | $896 | $198 | $86–$642 | $114 |
| 2021 | $7,758 | $361 | $118–$1,182 | $132 |
| 2022 | $2,573 | $410 | $128–$1,175 | $149 |
| 2023 | $285 | $434 | $152–$1,344 | $160 |
| 2024 | $11,547 | $494 | $193–$1,331 | $164 |
| 2025 | $26,398 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
873
Drug cost
$251,690
Branded share of claims
54.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 179 | $129,149 | |
| Gemtesa Vibegron | Brand | 58 | $51,183 | |
| Xtampza Er Oxycodone Myristate | Brand | 11 | $22,489 | |
| Estradiol | Generic | 159 | $15,088 | |
| Premarin Estrogens, Conjugated | Brand | 20 | $9,050 | |
| Methenamine Hippurate | Generic | 123 | $8,499 | |
| Mirabegron Er Mirabegron | Brand | 14 | $7,750 | |
| Yuvafem Estradiol | Brand | 17 | $1,865 | |
| Desmopressin Acetate | Generic | 32 | $1,609 | |
| Trospium Chloride Er Trospium Chloride | Brand | 15 | $1,492 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 55 billing codesPaid by Medicare
$191,083
Medicare patients
377
Services billed
6,397
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 64% | |
| Osteoporosis | 32% | |
| Ischemic heart disease | 22% | |
| Depression | 21% | |
| Diabetes | 19% | |
| Chronic kidney disease | 16% | |
| Atrial fibrillation | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 30 | 4,804 | $23,946 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
174 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Virginia
Seyed Shobeiri
Urogynecology and Reconstructive Pelvic Surgery · Falls Church, VA
Nathan Guerette
Urogynecology and Reconstructive Pelvic Surgery · Midlothian, VA
Eric Chang
Urogynecology and Reconstructive Pelvic Surgery · Stafford, VA
Patricia Mwesigwa
Urogynecology and Reconstructive Pelvic Surgery · Arlington, VA
Anna Trikhacheva
Urogynecology and Reconstructive Pelvic Surgery · Portsmouth, VA
Walter Von Pechmann
Urogynecology and Reconstructive Pelvic Surgery · Annandale, VA
Related records
Urogynecology and Reconstructive Pelvic Surgery in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.